ArticleCase reports in oncology
Palliative Radiotherapy for Multiple Liver Metastases of Merkel Cell Carcinoma: A Case Report.
Article in Case reports in oncology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: There have been few reports of the efficacy of palliative radiotherapy (RT) for liver metastases of Merkel cell carcinoma (MCC). A case of a patient with gastrointestinal symptoms and liver dysfunction caused by multiple liver metastases of MCC is presented. Palliative RT improved the symptoms and liver function, enabling the continuation of systemic therapy. Case Presentation: A 66-year-old woman presented with metastatic MCC. Palliative RT (20 Gy in 5 fractions) was administered to the metastases extending from thoracic vertebra 11 to lumbar vertebra 1, and metastases in the left lobe of the liver were unintentionally partially included in the irradiation field. After palliative RT, avelumab therapy was initiated, but she complained of nausea and loss of appetite. Subsequent evaluations showed liver dysfunction and rapid progression of liver metastases. Palliative RT (20 Gy in 5 fractions) was administered to the right lobe of the liver, avoiding overlap with the previously irradiated area. Two weeks after RT, the patient showed significant improvement in the symptoms and liver function. The patient experienced no significant adverse events. She continued avelumab treatment, but she died 2 months after palliative RT to the right lobe of the liver due to progression of the MCC. Conclusion: Palliative RT should be considered a treatment option for patients with MCC who develop symptomatic liver metastases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.